Drug Database
Back to search

Poland· PL-100473487

Sorbifer Durules

A ferrous sulfate product containing ferrosi sulfas + acidum ascorbicum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.

ATC B03AA07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSorbifer DurulesATCB03AA07REGISTER NO.PL-100473487PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ferrosi sulfas + acidum ascorbicumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ferrous sulfate is registered in 10 of 19 countries.

Countries holding a registration under ATC B03AA07 (ferrous sulfate), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search ferrous sulfate products by name

Ferrous sulfate · ATC B03AA07

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ferrous sulfate costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ferrous sulfate · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$0.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ferrosi sulfas + Acidum ascorbicum
Manufacturer
InPharm Sp. z o.o.
Country
Poland (PL)
ATC code
B03AA07
ATC class
Ferrous sulfate
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991496357

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

80 interactions on record for ferrous sulfate.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ferrous sulfate against other medicinesHow interaction checks work

Ferrous sulfate · interactions on record

80 records

  • 3 severe
  • 68 moderate
  • 7 minor

Most severe, free to view

  • DolutegravirJ05AJ03severe
  • DolutegravirJ05AX12severe
  • DimercaprolV03AB09severe
  • Magnesium carbonateA02AA01moderate

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ferrous sulfate in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ferrous sulfate products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Germany · Taxofit
  • France · Fero-Grad Vitamine C, Timoferol

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cc967027-008f-4eca-8526-2d630d3eaa99
GET /v1/drugs/cc967027-008f-4eca-8526-2d630d3eaa99?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "100 mg Fe(II) + 60 mg",
  "packaging": "05909991496357 ¦ Rp ¦ 146891\n120 tabl.",
  "substance": "Ferrosi sulfas 100 mg Fe(II) + Acidum ascorbicum 60 mg",
  "common_name": "Ferrosi sulfas + Acidum ascorbicum",
  "pl_product_id": "100473487",
  "pozwolenie_nr": "343/22",
  "auth_procedure": "IR",
  "authorisation_validity": "2027-09-20"
}
API referenceMCP serverPlans

See everything about ferrous sulfate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console